Data / Drug companies / Cosette Pharmaceuticals, Inc.
Cosette Pharmaceuticals, Inc.: 95 products in the FDA NDC directory, labeler code 0713
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Cosette Pharmaceuticals, Inc. (labeler code 0713) lists 95 products in the FDA National Drug Code Directory, covering 47 finished drugs by generic name. By type: 90 prescription drugs, 5 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 1, 2026.
The request: Watch Cosette Pharmaceuticals, Inc. (FDA labeler code 0713): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0713
- Products in commercial distribution
- 95
- Packages
- 148
- Finished drugs by generic name
- 47
- Prescription products
- 90
- Over the counter products
- 5
- Controlled substance products
- Schedule IV 4, Schedule V 1
- Flagged as original packager
- 95 of 95 products that carry the flag
- Started marketing in the last 12 months
- 6
- Earliest marketing start
- March 24, 1983
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 59 | 62.1% |
| New drug applications (NDA) | 31 | 32.6% |
| Over the counter monograph drugs | 3 | 3.2% |
| Other unapproved drugs | 2 | 2.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 90 | 94.7% |
| Over the counter drugs | 5 | 5.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 23 | 24.2% |
| Cream | 20 | 21.1% |
| Ointment | 15 | 15.8% |
| Suppository | 8 | 8.4% |
| Gel | 6 | 6.3% |
| Solution | 4 | 4.2% |
| Tablet, coated | 4 | 4.2% |
| Suspension | 3 | 3.2% |
| Capsule | 2 | 2.1% |
| Lotion | 2 | 2.1% |
| Injection | 2 | 2.1% |
| Shampoo, suspension | 1 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Benicar HCT | 0713-0945 | Tablet, film coated | New drug applications (NDA) | April 1, 2026 |
| Benicar HCT | 0713-0943 | Tablet, film coated | New drug applications (NDA) | April 1, 2026 |
| Benicar HCT | 0713-0944 | Tablet, film coated | New drug applications (NDA) | March 3, 2026 |
| Promethazine Hydrochloride and Codeine Phosphate | 0713-0823 | Solution | Generic drugs (ANDA) | December 19, 2025 |
| Ciprofloxacin hydrochloride and hydrocortisone | 0713-0851 | Suspension/ drops | Generic drugs (ANDA) | December 4, 2025 |
| Vyleesi | 0713-0897 | Injection | New drug applications (NDA) | November 12, 2025 |
| Promethazine Hydrochloride and Dextromethorphan Hydrobromide | 0713-0780 | Solution | Generic drugs (ANDA) | September 19, 2025 |
| Benicar | 0713-0942 | Tablet, film coated | New drug applications (NDA) | August 1, 2025 |
| Benicar | 0713-0941 | Tablet, film coated | New drug applications (NDA) | August 1, 2025 |
| Benicar | 0713-0940 | Tablet, film coated | New drug applications (NDA) | August 1, 2025 |
| Tazarotene | 0713-0765 | Cream | Generic drugs (ANDA) | March 10, 2025 |
| Ambien CR | 0713-5521 | Tablet, coated | New drug applications (NDA) | February 7, 2025 |
| Ambien CR | 0713-5501 | Tablet, coated | New drug applications (NDA) | February 7, 2025 |
| Ambien | 0713-5421 | Tablet, film coated | New drug applications (NDA) | February 7, 2025 |
| Ambien | 0713-5401 | Tablet, film coated | New drug applications (NDA) | February 7, 2025 |
| Ketoconazole | 0713-0592 | Shampoo, suspension | Generic drugs (ANDA) | February 7, 2025 |
| MICONAZOLE 3 COMBINATION PACK (miconazole nitrate) kit | 0713-0593 | Kit | Generic drugs (ANDA) | January 3, 2025 |
| Sucralfate | 0713-0791 | Suspension | Generic drugs (ANDA) | December 19, 2024 |
| Calcipotriene and betamethasone dipropionate | 0713-0848 | Suspension | Generic drugs (ANDA) | August 2, 2024 |
| Nitroglycerin | 0713-0564 | Ointment | Generic drugs (ANDA) | February 23, 2024 |
| Hydrocortisone and acetic acid | 0713-0849 | Solution | Generic drugs (ANDA) | February 1, 2024 |
| Docosanol | 0713-0353 | Cream | Generic drugs (ANDA) | January 4, 2024 |
| Metronidazole | 0713-0575 | Gel | Generic drugs (ANDA) | July 12, 2023 |
| Dapsone | 0713-0886 | Gel | Generic drugs (ANDA) | May 8, 2023 |
| Metronidazole | 0713-0574 | Gel | Generic drugs (ANDA) | February 1, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.